Company intelligence

Coherus Oncology

We are in the business of extending life for patients.

Biotechnology Research
Redwood City, US
201–500 employees
Founded 2010
2 public signals

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

Verified activity

Signals from Coherus Oncology

2 published signals

Find the companies already in motion.

Customize signals around your market, buyers, competitors, and investment thesis.

© 2026 SeedOpsCompany intelligence.

SeedOps.